drugset
drugset / Trial / NCT00707590

Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT00707590 ↗

Phase 1 Terminated 120 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

To assess the safety and tolerability and the PK/PD relationship of BMS-767778 administered as single and multiple oral doses in healthy subjects, and in subjects with T2DM

Timeline

Start
2008-08
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-767778 Unknown 1 mg Oral
Subject BMS-767778 Unknown 3 mg Oral
Subject BMS-767778 Unknown 10 mg Oral
Subject BMS-767778 Unknown 30 mg Oral
Subject BMS-767778 Unknown 100 mg Oral
Subject BMS-767778 Unknown 300 mg Oral
Subject BMS-767778 Unknown 600 mg Oral

Indications

type 2 diabetes mellitus